Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

In a remarkable achievement, a paralyzed and nonverbal patient with a Neuralink chip was able to edit a video using only his brain signals.

The first nonverbal Neuralink patient to receive the chip implant is offering a glimpse into how he uses the technology – editing and narrating a YouTube video using signals from his brain.

A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the ...

Learn more about whether argenx SE or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Brad Smith is the third person in the world to get a brain chip implant with Elon Musk's Neuralink, and the first nonverbal ...